29 results on '"Buus, Terkild B."'
Search Results
2. Keratinocytes Present Staphylococcus aureus Enterotoxins and Promote Malignant and Nonmalignant T Cell Proliferation in Cutaneous T-Cell Lymphoma
- Author
-
Zeng, Ziao, Vadivel, Chella Krishna, Gluud, Maria, Namini, Martin R.J., Yan, Lang, Ahmad, Sana, Hansen, Morten Bagge, Coquet, Jonathan, Mustelin, Tomas, Koralov, Sergei B., Bonefeld, Charlotte Menne, Woetmann, Anders, Geisler, Carsten, Guenova, Emmanuella, Kamstrup, Maria R., Litman, Thomas, Gjerdrum, Lise-Mette R., Buus, Terkild B., and Ødum, Niels
- Published
- 2024
- Full Text
- View/download PDF
3. mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection
- Author
-
Ivanova, Ellie N., Shwetar, Jasmine, Devlin, Joseph C., Buus, Terkild B., Gray-Gaillard, Sophie, Koide, Akiko, Cornelius, Amber, Samanovic, Marie I., Herrera, Alberto, Mimitou, Eleni P., Zhang, Chenzhen, Karmacharya, Trishala, Desvignes, Ludovic, Ødum, Niels, Smibert, Peter, Ulrich, Robert J., Mulligan, Mark J., Koide, Shohei, Ruggles, Kelly V., Herati, Ramin S., and Koralov, Sergei B.
- Published
- 2023
- Full Text
- View/download PDF
4. KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance
- Author
-
Zavitsanou, Anastasia-Maria, Pillai, Ray, Hao, Yuan, Wu, Warren L., Bartnicki, Eric, Karakousi, Triantafyllia, Rajalingam, Sahith, Herrera, Alberto, Karatza, Angeliki, Rashidfarrokhi, Ali, Solis, Sabrina, Ciampricotti, Metamia, Yeaton, Anna H., Ivanova, Ellie, Wohlhieter, Corrin A., Buus, Terkild B., Hayashi, Makiko, Karadal-Ferrena, Burcu, Pass, Harvey I., Poirier, John T., Rudin, Charles M., Wong, Kwok-Kin, Moreira, Andre L., Khanna, Kamal M., Tsirigos, Aristotelis, Papagiannakopoulos, Thales, and Koralov, Sergei B.
- Published
- 2023
- Full Text
- View/download PDF
5. Endolysin Inhibits Skin Colonization by Patient-Derived Staphylococcus Aureus and Malignant T-Cell Activation in Cutaneous T-Cell Lymphoma
- Author
-
Pallesen, Emil M.H., Gluud, Maria, Vadivel, Chella Krishna, Buus, Terkild B., de Rooij, Bob, Zeng, Ziao, Ahmad, Sana, Willerslev-Olsen, Andreas, Röhrig, Christian, Kamstrup, Maria R., Bay, Lene, Lindahl, Lise, Krejsgaard, Thorbjørn, Geisler, Carsten, Bonefeld, Charlotte M., Iversen, Lars, Woetmann, Anders, Koralov, Sergei B., Bjarnsholt, Thomas, Frieling, Johan, Schmelcher, Mathias, and Ødum, Niels
- Published
- 2023
- Full Text
- View/download PDF
6. Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma
- Author
-
Gluud, Maria, Pallesen, Emil M. H., Buus, Terkild B., Gjerdrum, Lise Mette Rahbek, Lindahl, Lise M., Kamstrup, Maria R., Bzorek, Michael, Danielsen, Maria, Bech, Rikke, Monteiro, Madalena N., Blümel, Edda, Willerslev-Olsen, Andreas, Lykkebo-Valløe, Anders, Vadivel, Chella Krishna, Krejsgaard, Thorbjørn, Bonefeld, Charlotte Menne, Geisler, Carsten, Becker, Jürgen C., Koralov, Sergei B., Iversen, Lars, Litman, Thomas, Woetmann, Anders, and Ødum, Niels
- Published
- 2023
- Full Text
- View/download PDF
7. Single-cell RNA and T-cell receptor sequencing unveil mycosis fungoides heterogeneity and a possible gene signature.
- Author
-
Srinivas, Nalini, Peiffer, Lukas, Horny, Kai, Kuan Cheok Lei, Buus, Terkild B., Kubat, Linda, Meng Luo, Menghong Yin, Spassova, Ivelina, Sucker, Antje, Farahpour, Farnoush, Kehrmann, Jan, Ugurel, Selma, Livingstone, Elisabeth, Gambichler, Thilo, Ødum, Niels, and Becker, Jürgen C.
- Subjects
CYTOTOXIC T cells ,CUTANEOUS T-cell lymphoma ,DRUG eruptions ,CANCER cells ,T cells ,MYCOSIS fungoides - Abstract
Background: Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL). Comprehensive analysis of MF cells in situ and ex vivo is complicated by the fact that is challenging to distinguish malignant from reactive T cells with certainty. Methods: To overcome this limitation, we performed combined single-cell RNA (scRNAseq) and T-cell receptor TCR sequencing (scTCRseq) of skin lesions of cutaneous MF lesions from 12 patients. A sufficient quantity of living T cells was obtained from 9 patients, but 2 had to be excluded due to unclear diagnoses (coexisting CLL or revision to a fixed toxic drug eruption). Results: From the remaining patients we established single-cell mRNA expression profiles and the corresponding TCR repertoire of 18,630 T cells. TCR clonality unequivocally identified 13,592 malignant T cells. Reactive T cells of all patients clustered together, while malignant cells of each patient formed a unique cluster expressing genes typical of naive/memory, such as CD27, CCR7 and IL7R, or cytotoxic T cells, e.g., GZMA, NKG7 and GNLY. Genes encoding classic CTCL markers were not detected in all clusters, consistent with the fact that mRNA expression does not correlate linearly with protein expression. Nevertheless, we successfully pinpointed distinctive gene signatures differentiating reactive malignant from malignant T cells: keratins (KRT81, KRT86), galectins (LGALS1, LGALS3) and S100 genes (S100A4, S100A6) being overexpressed in malignant cells. Conclusions: Combined scRNAseq and scTCRseq not only allows unambiguous identification of MF cells, but also revealed marked heterogeneity between and within patients with unexpected functional phenotypes. While the correlation between mRNA and protein abundance was limited with respect to established MF markers, we were able to identify a single-cell gene expression signature that distinguishes malignant from reactive T cells. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Staphylococcus aureus Induces Signal Transducer and Activator of Transcription 5‒Dependent miR-155 Expression in Cutaneous T-Cell Lymphoma
- Author
-
Willerslev-Olsen, Andreas, Gjerdrum, Lise Mette Rahbek, Lindahl, Lise M., Buus, Terkild B., Pallesen, Emil M.H., Gluud, Maria, Bzorek, Michael, Nielsen, Boye S., Kamstrup, Maria R., Rittig, Anne Hald, Bonefeld, Charlotte M., Krejsgaard, Thorbjørn, Geisler, Carsten, Koralov, Sergei B., Litman, Thomas, Becker, Jurgen C., Woetmann, Anders, Iversen, Lars, and Odum, Niels
- Published
- 2021
- Full Text
- View/download PDF
9. Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma
- Author
-
Lindahl, Lise M., Willerslev-Olsen, Andreas, Gjerdrum, Lise M.R., Nielsen, Pia R., Blümel, Edda, Rittig, Anne H., Celis, Pamela, Herpers, Bjorn, Becker, Jürgen C., Stausbøl-Grøn, Birgitte, Wasik, Mariusz A., Gluud, Maria, Fredholm, Simon, Buus, Terkild B., Johansen, Claus, Nastasi, Claudia, Peiffer, Lukas, Kubat, Linda, Bzorek, Michael, Eriksen, Jens O., Krejsgaard, Thorbjørn, Bonefeld, Charlotte M., Geisler, Carsten, Mustelin, Tomas, Langhoff, Erik, Givskov, Michael, Woetmann, Anders, Kilian, Mogens, Litman, Thomas, Iversen, Lars, and Odum, Niels
- Published
- 2019
- Full Text
- View/download PDF
10. SATB1 in Malignant T Cells
- Author
-
Fredholm, Simon, Willerslev-Olsen, Andreas, Met, Özcan, Kubat, Linda, Gluud, Maria, Mathiasen, Sarah L., Friese, Christina, Blümel, Edda, Petersen, David L., Hu, Tengpeng, Nastasi, Claudia, Lindahl, Lise M., Buus, Terkild B., Krejsgaard, Thorbjørn, Wasik, Mariusz A., Kopp, Katharina L., Koralov, Sergei B., Persson, Jenny L., Bonefeld, Charlotte M., Geisler, Carsten, Woetmann, Anders, Iversen, Lars, Becker, Jürgen C., and Ødum, Niels
- Published
- 2018
- Full Text
- View/download PDF
11. Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome
- Author
-
Willerslev-Olsen, Andreas, Buus, Terkild B., Nastasi, Claudia, Blümel, Edda, Gluud, Maria, Bonefeld, Charlotte M., Geisler, Carsten, Lindahl, Lise M., Vermeer, Maarten, Wasik, Mariusz A., Iversen, Lars, Becker, Jürgen C., Andersen, Mads Hald, Gjerdrum, Lise M. R., Litvinov, Ivan V., Litman, Thomas, Krejsgaard, Thorbjørn, Woetmann, Anders, and Ødum, Niels
- Published
- 2020
- Full Text
- View/download PDF
12. Phenotypic plasticity of malignant T cells in blood and skin of a Sézary syndrome patient revealed by single cell transcriptomics.
- Author
-
Peiffer, Lukas, Gambichler, Thilo, Buus, Terkild B., Horny, Kai, Gravemeyer, Jan, Furtmann, Frauke, Spassova, Ivelina, Kubat, Linda, Susok, Laura, Stranzenbach, René, Srinivas, Nalini, Ødum, Niels, and Becker, Jürgen C.
- Subjects
CANCER cells ,T cells ,BLOOD cells ,SEZARY syndrome ,PHENOTYPIC plasticity - Abstract
Background: Sézary Syndrome (SS) is an aggressive leukemic variant of cutaneous T-cell lymphomas (CTCL). In SS patients, malignant T cells are circulating through the blood and cause erythroderma. Objective: To compare the transcriptome of single cells in blood and skin samples from a patient with advanced SS. Methods: We utilized combined single cell RNA and T-cell receptor (TCR) sequencing (scRNA-seq). Results: We scrutinized the malignant T cells in blood and skin in an unbiased manner without pre-sorting of cells. We observed different phenotypes of the same monoclonal malignant T-cell population, confirmed by TCR sequencing and inferred copy number variation analysis. Malignant T cells present in the circulating blood expressed genes resembling central memory T cells such as CCR7, IL7R and CD27. In the skin, we detected two major malignant T-cell populations: One subpopulation was closely related to the malignant T cells from the blood, while the other subpopulation expressed genes reminiscent of skin resident effector memory T cells including GZMB and NKG7. Pseudotime analysis indicated crucial transcriptomic changes in the transition of malignant T cells between blood and skin. These changes included the differential regulation of TXNIP, a putative tumor suppressor in CTCL, and the adaptation to the hypoxic conditions in the skin. Tumor cell proliferation in the skin was supported by stimulating interactions between myeloid cells and malignant T cells. Conclusions: Using scRNA-seq we detected a high degree of functional heterogeneity within the malignant T-cell population in SS and highlighted crucial differences between SS cells in blood and skin. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Fine-tuning of T-cell development by the CD3γ di-leucine-based TCR-sorting motif
- Author
-
Lauritsen, Jens Peter H., Boding, Lasse, Buus, Terkild B., Kongsbak, Martin, Levring, Trine B., Rode, Anna K. O., Bonefeld, Charlotte Menné, and Geisler, Carsten
- Published
- 2015
- Full Text
- View/download PDF
14. Low SATB1 Expression Promotes IL-5 and IL-9 Expression in Sézary Syndrome
- Author
-
Herrera, Alberto, Fredholm, Simon, Cheng, Anthony, Mimitou, Eleni P., Seffens, Angelina, Bar-Natan, Michal, Sun, Amy, Latkowski, Jo-Ann, Willerslew-Olsen, Andreas, Buus, Terkild B., Gluud, Maria, Krejsgaard, Thorbjørn, Torres-Rusillo, Sara, Bonefeld, Charlotte Menné, Woetmann, Anders, Geisler, Carsten, Geskin, Larisa J., Ouyang, Zhengqing, Smibert, Peter, Ødum, Niels, and Koralov, Sergei B.
- Published
- 2020
- Full Text
- View/download PDF
15. Impaired Vitamin D Signaling in T Cells From a Family With Hereditary Vitamin D Resistant Rickets.
- Author
-
Al-Jaberi, Fatima A. H., Kongsbak-Wismann, Martin, Aguayo-Orozco, Alejandro, Krogh, Nicolai, Buus, Terkild B., Lopez, Daniel V., Rode, Anna K. O., Gravesen, Eva, Olgaard, Klaus, Brunak, Søren, Woetmann, Anders, Ødum, Niels, Bonefeld, Charlotte M., and Geisler, Carsten
- Subjects
VITAMIN D ,T cells ,VITAMIN D receptors ,RETINOID X receptors ,VITAMIN A ,RICKETS - Abstract
The active form of vitamin D, 1,25-dihydroxyvitamin D
3 (1,25(OH)2 D3 ), mediates its immunomodulatory effects by binding to the vitamin D receptor (VDR). Here, we describe a new point mutation in the DNA-binding domain of the VDR and its consequences for 1,25(OH)2 D3 signaling in T cells from heterozygous and homozygous carriers of the mutation. The mutation did not affect the overall structure or the ability of the VDR to bind 1,25(OH)2 D3 and the retinoid X receptor. However, the subcellular localization of the VDR was strongly affected and the transcriptional activity was abolished by the mutation. In heterozygous carriers of the mutation, 1,25(OH)2 D3 -induced gene regulation was reduced by ~ 50% indicating that the expression level of wild-type VDR determines 1,25(OH)2 D3 responsiveness in T cells. We show that vitamin D-mediated suppression of vitamin A-induced gene regulation depends on an intact ability of the VDR to bind DNA. Furthermore, we demonstrate that vitamin A inhibits 1,25(OH)2 D3 -induced translocation of the VDR to the nucleus and 1,25(OH)2 D3 -induced up-regulation of CYP24A1. Taken together, this study unravels novel aspects of vitamin D signaling and function of the VDR in human T cells. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
16. Improving oligo-conjugated antibody signal in multimodal single-cell analysis.
- Author
-
Buus, Terkild B., Herrera, Alberto, Ivanova, Ellie, Mimitou, Eleni, Cheng, Anthony, Herati, Ramin S., Papagiannakopoulos, Thales, Smibert, Peter, Odum, Niels, and Koralov, Sergei B.
- Subjects
- *
NUCLEOTIDE sequencing , *PROTEIN expression , *CELL populations , *IMMUNOGLOBULINS , *MONOCLONAL antibodies , *ANTIBODY formation , *STAINS & staining (Microscopy) - Abstract
Simultaneous measurement of surface proteins and gene expression within single cells using oligo-conjugated antibodies offers high-resolution snapshots of complex cell populations. Signal from oligo-conjugated antibodies is quantified by high-throughput sequencing and is highly scalable and sensitive. We investigated the response of oligo-conjugated antibodies towards four variables: concentration, staining volume, cell number at staining, and tissue. We find that staining with recommended antibody concentrations causes unnecessarily high background and amount of antibody used can be drastically reduced without loss of biological information. Reducing staining volume only affects antibodies targeting abundant epitopes used at low concentrations and is counteracted by reducing cell numbers. Adjusting concentrations increases signal, lowers background, and reduces costs. Background signal can account for a major fraction of total sequencing and is primarily derived from antibodies used at high concentrations. This study provides new insight into titration response and background of oligo-conjugated antibodies and offers concrete guidelines to improve such panels. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma.
- Author
-
Stolearenco, Veronica, Levring, Trine B., Nielsen, Helene Myrtue, Lindahl, Lise, Fredholm, Simon, Kongsbak-Wismann, Martin, Willerslev-Olsen, Andreas, Buus, Terkild B., Nastasi, Claudia, Hu, Tengpeng, Gluud, Maria, Côme, Christophe R.M., Krejsgaard, Thorbjørn, Iversen, Lars, Bonefeld, Charlotte Menné, Grønbæk, Kirsten, Met, Özcan, Woetmann, Anders, Ødum, Niels, and Geisler, Carsten
- Subjects
CUTANEOUS T-cell lymphoma ,THIOREDOXIN-interacting protein ,CANCER cells ,T cells ,CELL lines ,O6-Methylguanine-DNA Methyltransferase ,ANAPLASTIC lymphoma kinase - Abstract
Background: The thioredoxin-interacting protein (TXNIP) is involved in cellular metabolism and cell proliferation, and recently, deficient expression of TXNIP has been associated with progression and poor outcome for cancer patients. Objectives: To assess TXNIP expression and function in malignant T cells from cutaneous T-cell lymphoma (CTCL). Methods: CTCL-derived malignant (MyLa2059, PB2B) and non-malignant (MyLa1850) cell lines were analysed by Western blotting and qPCR for TXNIP expression. Subsequently, the malignant CTCL cell lines were treated with GSK126 – an inhibitor of enhancer of zeste homolog 2 (EZH2) methyltransferase activity or assessed by bisulphite sequencing for TXNIP promoter methylation. Methylation was also assessed with the demethylating agent 5-azacytidine (5AZA). Finally, TXNIP was overexpressed in the malignant PB2B cell line via plasmid transduction, and the effect of TXNIP was further analysed by flow cytometry. Results: We report on low expression of TXNIP protein in all cell lines representing different subtypes and stages of CTCL when compared to non-malignant T cells. Epigenetic silencing and other mechanisms were involved in the repression of TXNIP whereas forced expression of TXNIP strongly inhibited proliferation of malignant T cells. Conclusions: Epigenetic silencing and other as yet unknown mechanisms repress TXNIP expression in malignant T cells. As forced expression of TXNIP inhibits malignant proliferation, we propose that TXNIP is a putative tumour suppressor in CTCL. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. The major diversification of Vγ1.1+ and Vγ2+ thymocytes in mice occurs after commitment to the γδ T-cell lineage.
- Author
-
Buus, Terkild B., Geisler, Carsten, and Lauritsen, Jens Peter H.
- Abstract
γδ T cells are a heterogeneous cell population with different subsets playing specialized and often opposing roles during immune responses. A key question is whether γδ thymocytes are determined for their effector function already at an early stage, before their commitment to the γδ T-cell lineage, or are instructed during their later development. Here, we show that the adult Vγ1.1
+ and Vγ2+ γδ T-cell subsets both go through a CD73+ CD24+ development stage, and that the gene regulation involved in lineage commitment is shared by both subsets. We demonstrate that the major subset diversification first occurs after the cells have committed to the γδ T-cell lineage, strongly supporting an instructive model for functional programming of γδ T cells. In conclusion, we show that the two major adult γδ T-cell subsets in mice develop through a shared pathway utilizing similar cellular machinery and that they diverge after the CD24+ CD73+ maturity stage. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
19. JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL).
- Author
-
Vadivel, Chella Krishna, Gluud, Maria, Torres-Rusillo, Sara, Boding, Lasse, Willerslev-Olsen, Andreas, Buus, Terkild B., Nielsen, Tea Kirkegaard, Persson, Jenny L., Bonefeld, Charlotte M., Geisler, Carsten, Krejsgaard, Thorbjorn, Fuglsang, Anja T., Odum, Niels, and Woetmann, Anders
- Subjects
CELL nuclei ,GENE expression ,PHOSPHORYLATION ,SKIN diseases ,T cells ,TRANSFERASES ,NUCLEAR proteins ,SEZARY syndrome ,T-cell lymphoma ,SIGNAL peptides ,IN vitro studies ,JANUS kinases - Abstract
Simple Summary: JAK3 plays an important role in the pathogenesis of cutaneous T cell lymphoma. JAK3 belongs to the Janus kinase family of receptor-associated tyrosine kinases located in cytoplasm adjacent to the plasma membrane. In this study, we show that JAK3 can also be ectopically expressed in the nucleus in CTCL cell lines and primary cells from CTCL patients. Importantly, JAK3 interacts with the nuclear protein RNA polymerase II and phosphorylates Histone H3. Thus, our data provide first evidence for nuclear expression of JAK3 and interactions with key nuclear proteins in malignant T cells suggesting a novel non-canonical role in CTCL. Perturbation in JAK-STAT signaling has been reported in the pathogenesis of cutaneous T cell lymphoma (CTCL). JAK3 is predominantly associated with the intra-cytoplasmic part of IL-2Rγc located in the plasma membrane of hematopoietic cells. Here we demonstrate that JAK3 is also ectopically expressed in the nucleus of malignant T cells. We detected nuclear JAK3 in various CTCL cell lines and primary malignant T cells from patients with Sézary syndrome, a leukemic variant of CTCL. Nuclear localization of JAK3 was independent of its kinase activity whereas STAT3 had a modest effect on nuclear JAK3 expression. Moreover, JAK3 nuclear localization was only weakly affected by blockage of nuclear export. An inhibitor of the nuclear export protein CRM1, Leptomycin B, induced an increased expression of SOCS3 in the nucleus, but only a weak increase in nuclear JAK3. Importantly, immunoprecipitation experiments indicated that JAK3 interacts with the nuclear protein POLR2A, the catalytic subunit of RNA Polymerase II. Kinase assays showed tyrosine phosphorylation of recombinant human Histone H3 by JAK3 in vitro—an effect which was blocked by the JAK inhibitor (Tofacitinib citrate). In conclusion, we provide the first evidence of nuclear localization of JAK3 in malignant T cells. Our findings suggest that JAK3 may have a cytokine-receptor independent function in the nucleus of malignant T cells, and thus a novel non-canonical role in CTCL. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas.
- Author
-
Gluud, Maria, Willerslev-Olsen, Andreas, Gjerdrum, Lise Mette Rahbek, Lindahl, Lise M., Buus, Terkild B., Andersen, Mads Hald, Bonefeld, Charlotte Menne, Krejsgaard, Thorbjorn, Litvinov, Ivan V., Iversen, Lars, Becker, Jürgen C., Persson, Jenny L., Koralov, Sergei B., Litman, Thomas, Geisler, Carsten, Woetmann, Anders, and Odum, Niels
- Subjects
SKIN disease diagnosis ,SKIN disease treatment ,MYCOSIS fungoides ,SKIN diseases ,T-cell lymphoma ,MICRORNA - Abstract
Cutaneous T-cell lymphoma (CTCL) represents a heterogeneous group of potentially devastating primary skin malignancies. Despite decades of intense research efforts, the pathogenesis is still not fully understood. In the early stages, both clinical and histopathological diagnosis is often difficult due to the ability of CTCL to masquerade as benign skin inflammatory dermatoses. Due to a lack of reliable biomarkers, it is also difficult to predict which patients will respond to therapy or progress towards severe recalcitrant disease. In this review, we discuss recent discoveries concerning dysregulated microRNA (miR) expression and putative pathological roles of oncogenic and tumor suppressive miRs in CTCL. We also focus on the interplay between miRs, histone deacetylase inhibitors, and oncogenic signaling pathways in malignant T cells as well as the impact of miRs in shaping the inflammatory tumor microenvironment. We highlight the potential use of miRs as diagnostic and prognostic markers, as well as their potential as therapeutic targets. Finally, we propose that the combined use of miR-modulating compounds with epigenetic drugs may provide a novel avenue for boosting the clinical efficacy of existing anti-cancer therapies in CTCL. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. STAT3 Dysregulation in Mature T and NK Cell Lymphomas.
- Author
-
Seffens, Angelina, Herrera, Alberto, Tegla, Cosmin, Buus, Terkild B., Hymes, Kenneth B., Ødum, Niels, Geskin, Larisa J., and Koralov, Sergei B.
- Subjects
CELLULAR signal transduction ,KILLER cells ,T-cell lymphoma ,SIGNAL peptides - Abstract
T cell lymphomas comprise a distinct class of non-Hodgkin's lymphomas, which include mature T and natural killer (NK) cell neoplasms. While each malignancy within this group is characterized by unique clinicopathologic features, dysregulation in the Janus tyrosine family of kinases/Signal transducer and activator of transcription (JAK/STAT) signaling pathway, specifically aberrant STAT3 activation, is a common feature among these lymphomas. The mechanisms driving dysregulation vary among T cell lymphoma subtypes and include activating mutations in upstream kinases or STAT3 itself, formation of oncogenic kinases which drive STAT3 activation, loss of negative regulators of STAT3, and the induction of a pro-tumorigenic inflammatory microenvironment. Constitutive STAT3 activation has been associated with the expression of targets able to increase pro-survival signals and provide malignant fitness. Patients with dysregulated STAT3 signaling tend to have inferior clinical outcomes, which underscores the importance of STAT3 signaling in malignant progression. Targeting of STAT3 has shown promising results in pre-clinical studies in T cell lymphoma lines, ex-vivo primary malignant patient cells, and in mouse models of disease. However, targeting this pleotropic pathway in patients has proven difficult. Here we review the recent contributions to our understanding of the role of STAT3 in T cell lymphomagenesis, mechanisms driving STAT3 activation in T cell lymphomas, and current efforts at targeting STAT3 signaling in T cell malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. Type 1 immunity enables neonatal thymic ILC1 production.
- Author
-
Tougaard, Peter, Pérez, Mario R., Steels, Wolf, Huysentruyt, Jelle, Verstraeten, Bruno, Vetters, Jessica, Divert, Tatyana, Gonçalves, Amanda, Roelandt, Ria, Takahashi, Nozomi, Janssens, Sophie, Buus, Terkild B., Taghon, Tom, Leclercq, Georges, and Vandenabeele, Peter
- Subjects
- *
INNATE lymphoid cells , *IMMUNITY , *CYTOMEGALOVIRUS diseases , *PERITONEUM , *VIRUS diseases - Abstract
Acute thymic atrophy occurs following type 1 inflammatory conditions such as viral infection and sepsis, resulting in cell death and disruption of T cell development. However, the impact type 1 immunity has on thymic-resident innate lymphoid cells (ILCs) remains unclear. Single-cell RNA sequencing revealed neonatal thymic-resident type 1 ILCs (ILC1s) as a unique and immature subset compared to ILC1s in other primary lymphoid organs. Culturing murine neonatal thymic lobes with the type 1 cytokines interleukin-12 (IL-12) and IL-18 resulted in a rapid expansion and thymic egress of KLRG1+CXCR6+ cytotoxic ILC1s. Live imaging showed the subcapsular thymic localization and exit of ILC1s following IL-12 + IL-18 stimulation. Similarly, murine cytomegalovirus infection in neonates resulted in thymic atrophy and subcapsular localization of thymic-resident ILC1s. Neonatal thymic grafting revealed that type 1 inflammation enhances the homing of cytokine-producing thymus-derived ILC1s to the liver and peritoneal cavity. Together, we show that type 1 immunity promotes the expansion and peripheral homing of thymic-derived ILC1s. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. mRNA COVID-19 vaccine elicits potent adaptive immune response without the persistent inflammation seen in SARS-CoV-2 infection.
- Author
-
Ivanova EN, Shwetar J, Devlin JC, Buus TB, Gray-Gaillard S, Koide A, Cornelius A, Samanovic MI, Herrera A, Mimitou EP, Zhang C, Karmacharya T, Desvignes L, Ødum N, Smibert P, Ulrich RJ, Mulligan MJ, Koide S, Ruggles KV, Herati RS, and Koralov SB
- Abstract
SARS-CoV-2 infection and vaccination elicit potent immune responses. Our study presents a comprehensive multimodal single-cell dataset of peripheral blood of patients with acute COVID-19 and of healthy volunteers before and after receiving the SARS-CoV-2 mRNA vaccine and booster. We compared host immune responses to the virus and vaccine using transcriptional profiling, coupled with B/T cell receptor repertoire reconstruction. COVID-19 patients displayed an enhanced interferon signature and cytotoxic gene upregulation, absent in vaccine recipients. These findings were validated in an independent dataset. Analysis of B and T cell repertoires revealed that, while the majority of clonal lymphocytes in COVID-19 patients were effector cells, clonal expansion was more evident among circulating memory cells in vaccine recipients. Furthermore, while clonal αβ T cell responses were observed in both COVID-19 patients and vaccine recipients, dramatic expansion of clonal γδT cells was found only in infected individuals. Our dataset enables comparative analyses of immune responses to infection versus vaccination, including clonal B and T cell responses. Integrating our data with publicly available datasets allowed us to validate our findings in larger cohorts. To our knowledge, this is the first dataset to include comprehensive profiling of longitudinal samples from healthy volunteers pre/post SARS-CoV-2 vaccine and booster.
- Published
- 2023
- Full Text
- View/download PDF
24. Oncogenic fusions JAK up CD8+ cytotoxic CTCL.
- Author
-
Buus TB and Koralov SB
- Subjects
- CD8-Positive T-Lymphocytes, Humans, Antineoplastic Agents, Lymphoma, T-Cell, Cutaneous genetics, Skin Neoplasms
- Published
- 2021
- Full Text
- View/download PDF
25. Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures.
- Author
-
Herrera A, Cheng A, Mimitou EP, Seffens A, George D, Bar-Natan M, Heguy A, Ruggles KV, Scher JU, Hymes K, Latkowski JA, Ødum N, Kadin ME, Ouyang Z, Geskin LJ, Smibert P, Buus TB, and Koralov SB
- Subjects
- Cells, Cultured, Humans, Lymphoma, T-Cell, Cutaneous genetics, Single-Cell Analysis, Skin Neoplasms genetics, Transcriptome, Tumor Cells, Cultured, Lymphoma, T-Cell, Cutaneous pathology, Skin Neoplasms pathology
- Abstract
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of mature T-cell neoplasms characterized by the accumulation of clonal malignant CD4+ T cells in the skin. The most common variant of CTCL, mycosis fungoides (MF ), is confined to the skin in early stages but can be accompanied by extracutaneous dissemination of malignant T cells to the blood and lymph nodes in advanced stages of disease. Sézary syndrome (SS), a leukemic form of disease, is characterized by significant blood involvement. Little is known about the transcriptional and genomic relationship between skin- and blood-residing malignant T cells in CTCL. To identify and interrogate malignant clones in matched skin and blood from patients with leukemic MF and SS, we combine T-cell receptor clonotyping with quantification of gene expression and cell surface markers at the single cell level. Our data reveal clonal evolution at a transcriptional and genetic level within the malignant populations of individual patients. We highlight highly consistent transcriptional signatures delineating skin- and blood-derived malignant T cells. Analysis of these 2 populations suggests that environmental cues, along with genetic aberrations, contribute to transcriptional profiles of malignant T cells. Our findings indicate that the skin microenvironment in CTCL promotes a transcriptional response supporting rapid malignant expansion, as opposed to the quiescent state observed in the blood, potentially influencing efficacy of therapies. These results provide insight into tissue-specific characteristics of cancerous cells and underscore the need to address the patients' individual malignant profiles at the time of therapy to eliminate all subclones., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
26. MicroRNA-106b Regulates Expression of the Tumour Suppressors p21 and TXNIP and Promotes Tumour Cell Proliferation in Mycosis Fungoides.
- Author
-
Lindahl LM, Gluud M, Emmanuel T, Thomsen EA, Hu T, Rittig AH, Celis P, Stolearenco V, Krejsgaard T, Johansen C, Willerslev-Olsen A, Buus TB, Woetmann A, Aagaard L, Geisler C, Litman T, Mikkelsen JG, Odum N, and Iversen L
- Subjects
- Carrier Proteins, Cell Proliferation, Humans, Prognosis, MicroRNAs genetics, Mycosis Fungoides genetics, Skin Neoplasms genetics
- Abstract
A prognostic 3-miRNA classifier for early-stage mycosis fungoides has been developed recently, with miR-106b providing the strongest prognostic power. The aim of this study was to investigate the molecular function of miR-106b in mycosis fungoides disease progression. The cellular localization of miR-106b in mycosis fungoides skin biopsies was determined by in situ hybridization. The regulatory role of miR-106b was assessed by transient miR-106b inhibitor/mimic transfection of 2 mycosis fungoides derived cell lines, followed by quantitative real-time PCR (RT-qPCR), western blotting and a proliferation assay. MiR-106b was found to be expressed by dermal T-lymphocytes in mycosis fungoides skin lesions, and miR-106b expression increased with advancing mycosis fungoides stage. Transfection of miR-106b in 2 mycosis fungoides derived cell lines showed that miR-106b represses the tumour suppressors cyclin-dependent kinase inhibitor 1 (p21) and thioredoxin-interacting protein (TXNIP) and promotes mycosis fungoides tumour cell proliferation. In conclusion, these results substantiate that miR-106b has both a functional and prognostic role in progression of mycosis fungoides.
- Published
- 2020
- Full Text
- View/download PDF
27. Cellular Interactions and Inflammation in the Pathogenesis of Cutaneous T-Cell Lymphoma.
- Author
-
Stolearenco V, Namini MRJ, Hasselager SS, Gluud M, Buus TB, Willerslev-Olsen A, Ødum N, and Krejsgaard T
- Abstract
Cutaneous T-cell lymphoma (CTCL) comprises a group of lymphoproliferative diseases characterized by the accumulation of malignant T cells in chronically inflamed skin lesions. In early stages, the disease presents as skin patches or plaques covering a limited area of the skin and normally follows an indolent course. However, in a subset of patients the cutaneous lesions develop into tumors and the malignant T cells may spread to the lymphatic system, blood and internal organs with fatal consequences. Despite intensive research, the mechanisms driving disease progression remain incompletely understood. While most studies have focused on cancer cell-intrinsic oncogenesis, such as genetic and epigenetic events driving malignant transformation and disease progression, an increasing body of evidence shows that the interplay between malignant T cells and non-malignant cells plays a crucial role. Here, we outline some of the emerging mechanisms by which tumor, stromal and epidermal interactions may contribute to the progression of CTCL with particular emphasis on the crosstalk between fibroblasts, keratinocytes and malignant T cells., (Copyright © 2020 Stolearenco, Namini, Hasselager, Gluud, Buus, Willerslev-Olsen, Ødum and Krejsgaard.)
- Published
- 2020
- Full Text
- View/download PDF
28. The major diversification of Vγ1.1 + and Vγ2 + thymocytes in mice occurs after commitment to the γδ T-cell lineage.
- Author
-
Buus TB, Geisler C, and Lauritsen JP
- Subjects
- 5'-Nucleotidase genetics, Animals, CD24 Antigen metabolism, Cell Differentiation, Cell Lineage, Cells, Cultured, Female, Mice, Mice, Inbred C57BL, Mice, Knockout, 5'-Nucleotidase metabolism, Receptors, Antigen, T-Cell, gamma-delta metabolism, T-Lymphocyte Subsets physiology, T-Lymphocytes physiology, Thymus Gland immunology
- Abstract
γδ T cells are a heterogeneous cell population with different subsets playing specialized and often opposing roles during immune responses. A key question is whether γδ thymocytes are determined for their effector function already at an early stage, before their commitment to the γδ T-cell lineage, or are instructed during their later development. Here, we show that the adult Vγ1.1
+ and Vγ2+ γδ T-cell subsets both go through a CD73+ CD24+ development stage, and that the gene regulation involved in lineage commitment is shared by both subsets. We demonstrate that the major subset diversification first occurs after the cells have committed to the γδ T-cell lineage, strongly supporting an instructive model for functional programming of γδ T cells. In conclusion, we show that the two major adult γδ T-cell subsets in mice develop through a shared pathway utilizing similar cellular machinery and that they diverge after the CD24+ CD73+ maturity stage., (© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)- Published
- 2016
- Full Text
- View/download PDF
29. The TCR ligand-inducible expression of CD73 marks γδ lineage commitment and a metastable intermediate in effector specification.
- Author
-
Coffey F, Lee SY, Buus TB, Lauritsen JP, Wong GW, Joachims ML, Thompson LF, Zúñiga-Pflücker JC, Kappes DJ, and Wiest DL
- Subjects
- Animals, Cell Lineage immunology, Ligands, Lymphopoiesis immunology, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, Mutant Strains, Mice, Transgenic, Models, Immunological, Precursor Cells, T-Lymphoid immunology, 5'-Nucleotidase metabolism, Receptors, Antigen, T-Cell, gamma-delta metabolism, T-Lymphocyte Subsets immunology
- Abstract
Numerous studies indicate that γδ T cell receptor (γδTCR) expression alone does not reliably mark commitment of early thymic progenitors to the γδ fate. This raises the possibility that the γδTCR is unable to intrinsically specify fate and instead requires additional environmental factors, including TCR-ligand engagement. We use single cell progenitor assays to reveal that ligand acts instructionally to direct adoption of the γδ fate. Moreover, we identify CD73 as a TCR ligand-induced cell surface protein that distinguishes γδTCR-expressing CD4(-)CD8(-) progenitors that have committed to the γδ fate from those that have not yet done so. Indeed, unlike CD73(-) γδTCR(+) progenitors, which largely adopt the αβ fate upon separation from the intrathymic selecting environment, those that express CD73 remain CD4(-)CD8(-) and committed to the γδ fate. CD73 is expressed by >90% of peripheral γδ cells, suggesting this is a common occurrence during development. Moreover, CD73 induction appears to mark a metastable intermediate stage before acquisition of effector function, suggesting that γδ lineage and effector fate are specified sequentially. These findings have important implications for the role of ligand in γδ lineage commitment and its relationship to the specification of effector fate.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.